secwatch.observer — SEC 8-K summary
======================================

Issuer:     Olema Pharmaceuticals, Inc. (OLMA)
CIK:        0001750284
Form:       8-K
Filed at:   2023-05-09T23:59:59+00:00
Accession:  0001558370-23-008811
Event type: earnings
Sentiment:  neutral
Materiality: 0.65
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Olema Pharma Q1 net loss $28.3M, cash $186M; Phase 3 trial of OP-1250 planned H2 2023
--------------------------------------------------------------------------------

- Cash, cash equivalents and marketable securities of $186.0M as of March 31, 2023, expected to fund operations into 2025.
- Net loss for Q1 2023 was $28.3M, compared to $23.0M in Q1 2022, with R&D expenses rising to $22.8M from $16.0M.
- Company plans to initiate pivotal Phase 3 monotherapy trial of OP-1250 in second-line metastatic breast cancer in H2 2023.
- Interim Phase 2 results of OP-1250 plus palbociclib to be presented at ESMO Breast Cancer on May 12, 2023.
- Non-GAAP R&D expenses were $19.7M (excl. $3.1M SBC) vs $12.9M YoY; includes $2.8M restructuring charge.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1750284/000155837023008811/0001558370-23-008811-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1750284/000155837023008811/olma-20230509x8k.htm
  HTML page:      https://secwatch.observer/filing/0001558370-23-008811

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer